CBD showed no clear advantage over placebo on primary behavior measures

Cannabidiol (CBD) Treatment for Severe Problem Behaviors in Autistic Boys: A Randomized Clinical Trial.

Journal of autism and developmental disorders • • Clinical Trial • Highly Relevant
🤖

AI Summary

This randomized, double-blind, placebo-controlled crossover trial asked whether plant-derived CBD was safe and reduced severe problem behaviors in autistic boys aged 7–14. Participants received CBD for eight weeks and placebo for eight weeks, with a four-week washout between phases. The primary measures were the Repetitive Behavior Scale-Revised, Child Behavior Checklist, and Autism Diagnostic Observation Schedule-2.

On the primary behavior measures, both treatment phases showed improvement on two scales, but there was no significant difference between CBD and placebo. The ADOS-2 improved during the placebo phase only; that result was no longer evident after accounting for the children’s other medications. Blinded clinical impressions indicated behavioral improvement with CBD in almost two-thirds of participants, while one-third showed no change or improved on placebo. The abstract reports an acceptable safety profile and a strong placebo effect. Overall, the trial did not establish clear efficacy across the broad behaviors measured; this abstract-based summary cannot determine which children, if any, may benefit, and medication effects on CBD levels or outcomes may matter.

💡 Key Findings

1
On the primary behavior scales, both phases showed improvement on two measures, but there was no significant difference between CBD and placebo.
High
95%
2
Blinded clinical impressions suggested improvement with CBD in almost two-thirds of participants; one-third had no change or improved on placebo.
High
90%
3
The ADOS-2 improved during placebo only, but this finding disappeared when other medications were included in the analysis.
High
90%
4
The abstract reports an acceptable safety profile and a strong placebo effect.
High
85%

📄 Original Abstract

Open-label and observational studies suggest cannabidiol (CBD) reduces problematic behaviors in autistic children. No controlled clinical trials have addressed safety, tolerability, and efficacy. We conducted a double-blind, placebo-controlled crossover study of plant-derived CBD (Epidiolex®) to determine safety, tolerability, and behavior effects in autistic boys. Autistic boys with severe behavior problems age 7-14 years were randomized to eight weeks of CBD up to 20 mg/kg/day and eight weeks of placebo separated by a four-week washout. Behavioral assessments were completed before and after each treatment phase. Plasma concentrations of CBD were quantified. Primary outcomes were changes in total score of the Repetitive Behavior Scale-Revised (RBS-R), Child Behavior Checklist (CBCL), and Autism Diagnostic Observation Schedule-2 (ADOS-2). Both groups improved on the RBS-R and CBCL, with no significant difference between groups. ADOS-2 scores improved in placebo group only, but this improvement disappeared when other medications taken by the children were included in the analyses. Blinded clinical impressions showed almost 2/3 of the participants had behavioral improvements with CBD; 1/3 showed either no change or improvement on placebo. A strong placebo effect was observed. CBD had an acceptable safety profile. We did not find CBD to be clearly effective at reducing the broad range of behaviors characterized by the primary outcome measures. There was clinically evident improvement with CBD in 2/3 of participants. A prominent placebo effect demonstrates the importance of placebo control in treatment studies. Medications taken for behavior may reduce blood levels of CBD and may affect outcome measures.Trial Registration https://clinicaltrials.gov NCT04517799 start date 6/1/2020.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.